NCT03732768

Who might be able to join this trial:

• You are willing and able to give written consent and follow the study plan
• You are 18 years of age or older
• You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by a tissue test
• Your cancer has come back but is still responding to platinum-based chemotherapy, and surgery to remove all visible tumors is possible
• Any side effects from past cancer treatments have mostly cleared up before starting the study drug (hair loss is excepted)
• You are able to carry out normal daily activities with little or no difficulty (confirm with trial site)
• Your kidneys are working well enough, based on blood and/or urine tests
• Your liver is working well enough, based on blood tests
• Your bone marrow is producing enough blood cells, based on blood tests
• Your blood clotting is within an acceptable range, based on a blood test
• If you could become pregnant, you have a negative pregnancy test before joining
• If you could become pregnant and have a male partner, you agree to use two reliable forms of contraception during the study and for at least 3 months after the last dose of the study drug

Who may not be able to join:

• You have a type of ovarian cancer that is not epithelial (such as germ cell tumors or sex-cord tumors), or a neuroendocrine tumor
• Your tumor has been classified as "borderline" (not fully cancerous)
• You have cancer that has spread to other organs, or you have cancer that has spread to the chest lymph nodes or is causing symptoms in the brain or nervous system
• You are pregnant or currently breastfeeding
• You have an active infection that requires antibiotics or medical monitoring, or you have recurring fevers linked to an active infection
• You have active liver disease, or test positive for active hepatitis B, hepatitis C, or HIV
• You have taken part in another clinical trial or received an experimental medicine within the past 28 days (or within a time frame based on that medicine's half-life)
• You are receiving or have recently received any other cancer treatment within 4 weeks before or after the study treatment
• You have had another type of cancer in the past 3 years (some exceptions apply, such as certain skin cancers or early-stage cervical cancer — confirm with trial site)
• You have or have had serious heart failure or significant heart disease
• You have any other health or mental health condition that the study doctor feels could put you at risk or affect the study results
• In the study doctor's opinion, you are unable to follow the study procedures or give proper informed consent
• You have received the drug bevacizumab (Avastin®) within 5 weeks before planned surgery
• You have a known allergy to any ingredient in the study drug
• You are currently under an official or court-ordered placement in an institution
• You are financially dependent on the company running the trial
• You currently have an active COVID-19 (SARS-CoV-2) infection

Important: Always verify eligibility with the trial site directly before applying.